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We demonstrate the use of a probabilistic generative model to explore the biomarker changes occurring as Alzheimer’s disease
develops and progresses. We enhanced the recently introduced event-based model for use with a multi-modal sporadic disease
data set. This allows us to determine the sequence in which Alzheimer’s disease biomarkers become abnormal without reliance
on a priori clinical diagnostic information or explicit biomarker cut points. The model also characterizes the uncertainty in the
ordering and provides a natural patient staging system. Two hundred and eighty-five subjects (92 cognitively normal, 129 mild
cognitive impairment, 64 Alzheimer’s disease) were selected from the Alzheimer’s Disease Neuroimaging Initiative with meas-
urements of 14 Alzheimer’s disease-related biomarkers including cerebrospinal fluid proteins, regional magnetic resonance
imaging brain volume and rates of atrophy measures, and cognitive test scores. We used the event-based model to determine
the sequence of biomarker abnormality and its uncertainty in various population subgroups. We used patient stages assigned by
the event-based model to discriminate cognitively normal subjects from those with Alzheimer’s disease, and predict conversion
from mild cognitive impairment to Alzheimer’s disease and cognitively normal to mild cognitive impairment. The model predicts
that cerebrospinal fluid levels become abnormal first, followed by rates of atrophy, then cognitive test scores, and finally
regional brain volumes. In amyloid-positive (cerebrospinal fluid amyloid-b1–425192 pg/ml) or APOE-positive (one or more
APOE4 alleles) subjects, the model predicts with high confidence that the cerebrospinal fluid biomarkers become abnormal
in a distinct sequence: amyloid-b1–42, phosphorylated tau, total tau. However, in the broader population total tau and phos-
phorylated tau are found to be earlier cerebrospinal fluid markers than amyloid-b1–42, albeit with more uncertainty. The model’s
staging system strongly separates cognitively normal and Alzheimer’s disease subjects (maximum classification accuracy of
99%), and predicts conversion from mild cognitive impairment to Alzheimer’s disease (maximum balanced accuracy of 77%
over 3 years), and from cognitively normal to mild cognitive impairment (maximum balanced accuracy of 76% over 5 years). By
fitting Cox proportional hazards models, we find that baseline model stage is a significant risk factor for conversion from both
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mild cognitive impairment to Alzheimer’s disease (P = 2.06  107) and cognitively normal to mild cognitive impairment
(P = 0.033). The data-driven model we describe supports hypothetical models of biomarker ordering in amyloid-positive and
APOE-positive subjects, but suggests that biomarker ordering in the wider population may diverge from this sequence. The
model provides useful disease staging information across the full spectrum of disease progression, from cognitively normal to
mild cognitive impairment to Alzheimer’s disease. This approach has broad application across neurodegenerative disease,
providing insights into disease biology, as well as staging and prognostication.
Keywords: event-based model; disease progression; Alzheimer’s disease; biomarkers; biomarker ordering
Abbreviations: ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADNI = Alzheimer’s Disease Neuroimaging
Initiative; CN-converters = cognitively normal subjects who convert to mild cognitive impairment at follow-up; CN-stable = cogni-
tively normal subjects with a stable cognitively normal diagnosis at follow-up; EBM = event-based model; FDG = fluorodeoxyglucose;
MCI-converters = mild cognitive impairment subjects who convert to Alzheimer’s disease at follow-up; MCI-stable = mild cognitive
impairment subjects with a stable mild cognitive impairment diagnosis at follow-up
Introduction
Existing biomarkers of Alzheimer’s disease provide complimentary
information for disease staging and differential diagnosis.
Determining the particular sequence and evolution of biomarker
abnormality potentially provides a mechanism to stage and stratify
patients throughout the full disease time course, and in particular,
during the presymptomatic phase. This helps reduce heterogeneity
in trial groups, match individuals to putative treatments, and
monitor treatment outcomes. Although new diagnostic criteria
now incorporate biomarkers to allow earlier diagnosis (Sperling
et al., 2011), the evidence base for this is relatively limited. A
major challenge of current Alzheimer’s disease research (Jack
et al., 2013a) is to construct models of disease progression that
estimate biomarker ordering and dynamics directly from real-world
data sets enabling quantitative evaluation of patient state.
Alzheimer’s disease is characterized pathologically by the build-
up of amyloid plaques and neurofibrillary tangles in brain tissue
(Braak and Braak, 1991). These pathologies are thought to pre-
cede downstream neurodegeneration (i.e. neuronal loss), which
leads to clinical symptoms. Biomarkers have been developed that
allow the pathological process of Alzheimer’s disease to be moni-
tored in vivo. The most well validated of these are CSF amyloid-
b1–42 (Blennow and Hampel, 2003) and amyloid PET imaging
(Klunk et al., 2004; Clark et al., 2011), which measure brain amyl-
oid pathology; CSF phosphorylated tau and total tau (Blennow
and Hampel, 2003), as measures of neurofibrillary tangle depos-
ition and neuroaxonal damage; fluorodeoxyglucose (FDG) PET
(Herholz, 2012), a measure of brain metabolism; volume and at-
rophy rate markers derived from structural MRI (Fox and Schott,
2004), which are used to measure the extent and rate of regional
neurodegeneration; and cognitive test scores such as the Mini-
Mental State Examination (McKhann et al., 1984), which measure
cognitive performance.
Hypothetical models of Alzheimer’s disease progression have
been proposed (Aisen et al., 2010; Frisoni et al., 2010; Jack
et al., 2010) that describe a distinct sequence in which different
biomarkers become abnormal. These models generally propose
that CSF amyloid-b1–42 and amyloid PET abnormalities precede
CSF total tau, FDG-PET hypometabolism and atrophy rate
measured from structural MRI, which all occur before a clinically
significant change in cognitive test scores. However, these models
are not informed directly by measured data sets. Jack et al. (2011)
have attempted to validate the ordering of a subset of these bio-
markers: CSF amyloid-b1–42, CSF total tau and hippocampal
volume; however, their results are dependent on choosing cut
points defining abnormal biomarker levels, which are not easy to
establish (Bartlett et al., 2012).
Various other attempts to determine biomarker ordering (Lo
et al., 2011; Fo¨rster et al., 2012; Landau et al., 2012) have
used a priori staging based on clinical diagnosis. This limits the
temporal resolution of these models, typically to three stages (pre-
symptomatic, mild cognitive impairment, and Alzheimer’s disease),
and so can provide only a crude ordering of a small number of
biomarkers. Other models (Bateman et al., 2012; Buchhave et al.,
2012) regress against a particular clinical measure to order bio-
markers with better temporal resolution. Bateman et al. (2012) use
time to disease onset (estimated from subject’s parents for pre-
symptomatic cases) in familial Alzheimer’s disease as the clinical
measure. The applicability of these results to sporadic Alzheimer’s
disease where the disease may play out differently remains to be
determined and depends on accurate estimates of age of symptom
onset. A similar approach in sporadic Alzheimer’s disease is to
stage subjects retrospectively by time to an Alzheimer’s disease
diagnosis. This requires a large elderly cohort to be followed
over a long time period to ensure that a significant proportion
of the cohort develops Alzheimer’s disease. Buchhave et al.
(2012) show such an analysis of CSF measures in subjects with
mild cognitive impairment. Villemagne et al. (2013) instead esti-
mate the rate of change of each biomarker in individuals and
integrate over all subjects to get an average biomarker trajectory
over time. However, as with the validation provided by Jack et al.
(2011), cut points are required to determine the ordering of the
biomarker trajectories.
The recently introduced event-based model (EBM) (Fonteijn
et al., 2012) provides a generative model of disease progression
that can learn the ordering of biomarker changes from large cross-
sectional (or short-term longitudinal to enable measurement of
rates of atrophy) data sets, as well as providing insights into the
uncertainty of the reconstructed ordering. The EBM defines the
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disease progression as a sequence of events at which individual
biomarkers become abnormal. The EBM is probabilistic in the
sense that it learns normal and abnormal distributions of bio-
marker values from the data, and so does not require a priori
staging or cut points. The EBM further enables the assignment
of each subject to a disease stage. Previous work (Fonteijn
et al., 2012) demonstrated the EBM’s ability to order biomarkers
and generate staging measures derived from imaging data, in gen-
etically defined disease and control populations (familial
Alzheimer’s disease and Huntington’s disease). However, the ori-
ginal EBM is not directly applicable to sporadic disease data sets,
which have significant proportions of misdiagnosed cases in the
patient group; and, particularly in Alzheimer’s disease research, a
poorly defined control group because a significant number (esti-
mated to be a third by the eighth decade) of apparently healthy
elderly individuals have biomarker evidence consistent with pre-
symptomatic Alzheimer’s disease (Rowe et al., 2010; Schott et al.,
2010).
Here we reformulate the EBM for multi-modal data from a
heterogeneous sporadic disease population. The new EBM accom-
modates a modest proportion of misdiagnosed patients as well as
allowing for presymptomatic cases contaminating the control
group. We apply this EBM to the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data set to obtain characteristic
biomarker orderings from various subgroups, as well as their un-
certainty. We demonstrate the fine-grained staging potential of
the EBM and its ability both to classify cognitively normal and
Alzheimer’s disease subjects and to predict conversion from mild
cognitive impairment to Alzheimer’s disease and cognitively
normal to mild cognitive impairment.
Materials and methods
Data description
Subjects
Data used in the preparation of this article were obtained from the
ADNI database (adni.loni.usc.edu). The ADNI was launched in 2003
by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug
Administration (FDA), private pharmaceutical companies and non-
profit organizations, as a $60 million, 5-year public-private partnership.
For up-to-date information, see http://www.adni-info.org. Written
consent was obtained from all participants, and the study was
approved by the Institutional Review Board at each participating
institution.
We downloaded data from LONI (www.loni.ucla.edu/ADNI/) on 5
February 2013, and included all 285 subjects (cognitively normal, mild
cognitive impairment or Alzheimer’s disease) that had a CSF examin-
ation at baseline, standardized cognitive assessment at baseline (for
details see www.adni-info.org/Scientists/Pdfs/adniproceduresman-
ual12.pdf), which included: the Mini-Mental State Examination
(McKhann et al., 1984), the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog) (Rosen et al., 1984) (modified 13-
item ADAS-Cog, which omits Item 13), and the Rey Auditory Verbal
Learning Test (Rey, 1958) (immediate recall score, i.e. the sum of trials
1 to 5), and useable 1.5 T MRI imaging at baseline and 1 year. Clinical
diagnosis (cognitively normal/mild cognitive impairment/Alzheimer’s
disease) was also recorded. Other possible biomarkers, e.g. FDG-PET
and amyloid PET, were not included in the present analysis because
they limit the number of available subjects: less than half of subjects
with CSF and MRI data at baseline underwent a FDG-PET scan at
baseline, and few had baseline amyloid PET imaging. CSF measures
of amyloid-b1–42, phosphorylated tau and total tau were performed
centrally, as previously described (Shaw et al., 2009). The CSF total
tau and phosphorylated tau data were log transformed to improve
normality. We downloaded APOE genotype, for which methods
have been published previously (Saykin et al., 2010), for each individ-
ual from the LONI website. For validation of the staging system
derived from the EBM, we downloaded the aforementioned set of
imaging, clinical and CSF data at 12- and 24-month follow-up time
points. For the CSF we downloaded longitudinal data over 4 years, so
as to obtain baseline, 12- and 24-month CSF data, which were pro-
cessed in the same batch. As an outcome measure, we downloaded
clinical diagnoses at all available time points up to 72 months.
Magnetic resonance imaging
Details of the MRI methodology have previously been described (Jack
et al., 2008). Cross-sectional regional measures of brain volume for
the hippocampus, entorhinal cortex, middle temporal gyrus, fusiform,
ventricles and whole brain, as well as total intracranial volume, were
calculated at baseline using FreeSurfer Version 4.3, which is docu-
mented and freely available for download online (http://surfer.nmr.
mgh.harvard.edu/). All regional volumes were normalized by dividing
by total intracranial volume for each subject.
Longitudinal measures of regional volume change between 0 and 12
months were obtained using the boundary shift integral (BSI): volume
change was measured for the whole brain using the KN-BSI method
(Leung et al., 2010b), and for the hippocampus using the MAPS-HBSI
method (Leung et al., 2010a).
Event set
The biomarkers available for all the subjects provide the following set
of 14 biomarker transition ‘events’, each of which corresponds to a
biomarker becoming abnormal, i.e. changing from the ‘control’ to
‘Alzheimer’s disease’ state: (i) three CSF events: amyloid-b1–42, phos-
phorylated tau and total tau; (ii) three cognitive events: ADAS-Cog,
Rey Auditory Verbal Learning Test and Mini-Mental State
Examination; (iii) six regional brain volume events: brain, ventricles,
hippocampus, entorhinal, mid temporal and fusiform volumes; and
(iv) two rates of atrophy events: rates of hippocampal and brain
atrophy.
Event sequences
We defined four population subgroups: (i) whole population, all sub-
jects; (ii) amyloid-positive (amyloid + ), subjects with CSF amyloid-b1–
425 192 pg/ml. This cut point was chosen according to the results of
Shaw et al. (2009) who determined cut points using a maximum ac-
curacy classification of autopsy confirmed patients with Alzheimer’s
disease and cognitively normal subjects; (iii) APOE-positive
(APOE + ), subjects with one or more APOE4 alleles; and (iv) amyl-
oid-positive APOE-positive (amyloid + APOE + ), subjects who are both
amyloid + and APOE + .
The event-based model
We estimated the most likely ordering of events and its uncertainty in
each subgroup using the EBM (Fonteijn et al., 2012). The EBM treats
each biomarker as either ‘normal’, i.e. non-pathological, or ‘abnormal’,
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i.e. as seen in Alzheimer’s disease. The switch from normal to abnor-
mal is termed an ‘event’. The occurrence of any particular event, Ei,
i ¼ 1 . . . l, is informed by the corresponding measurements xij of bio-
marker i in subject j, j ¼ 1 . . . J. The whole data set X ¼ fxijji ¼
1 . . . I, j ¼ 1 . . . Jg contains measurements of each biomarker in each
subject. The most likely ordering of the events is the sequence S
that maximizes the data likelihood
P XjSð Þ ¼
YJ
j¼1
XI
k¼0
PðkÞ
Yk
i¼1
P xijjEi
  YI
i¼kþ1
Pðxijj:EiÞ
 !" #
, ð1Þ
where PðxjEiÞ and Pðxj:EiÞ are the likelihoods of measurement x given
that biomarker i has or has not become abnormal, respectively, and
PðkÞ is the prior likelihood of being at stage k, i.e. events E1, . . . , Ek
have occurred, and events Ekþ1, . . . , EI have yet to occur, which we
assume is uniform. This uniform prior assumes no knowledge of any
patient’s disease stage a priori, which imposes the least information
possible on estimated orderings.
In addition to finding the most likely sequence, we can evaluate
PðXjSÞ for any sequence to establish the relative likelihood of all se-
quences. This provides insight into the uncertainty of the ordering. The
positional variance diagram (Fonteijn et al., 2012) (Fig. 1A–D) visual-
izes both the maximum likelihood sequence and its uncertainty by
plotting the likelihood that each event appears in each position in
the sequence, i.e. the entry of each position is
P
S2Sik PðXjSÞ where
Sik is the set of all sequences with event i at position k.
Model of the event distribution
Evaluation of Equation 1 requires models for each of the event distri-
butions, PðxjEiÞ and Pðxj:EiÞ. The original EBM in Fonteijn et al. (2012)
used a familial Alzheimer’s disease data set for which the control group
was well defined allowing direct estimation of Pðxj:EiÞ. In sporadic
Alzheimer’s disease, however, a significant proportion of the cogni-
tively normal control group may have presymptomatic Alzheimer’s dis-
ease. To counter this, we fitted a mixture of two normal distributions
to each biomarker separately using data from all subjects to obtain the
two models. To ensure a robust fit, particularly for biomarkers where
the distributions of the healthy and diseased population overlap sig-
nificantly, we constrain the standard deviations so that the standard
deviation of P xj:Eið Þ and PðxjEiÞ is less than or equal to that of the
cognitively normal and Alzheimer’s disease group, respectively. This is
a weak constraint designed simply to guide the mixture model away
from physically unrealistic solutions. Importantly, while this modelling
approach can be used to determine fixed cut points for each bio-
marker, the model here is not dependent on these cut points, using
a probability function to determine the most likely sequencing of event
switches.
For specific details of the model fitting procedure for the EBM see
the online Supplementary material.
Cross-validation of event sequence
We performed cross-validation of the maximum likelihood event se-
quence returned by the EBM (Fig. 1E–H) by re-estimating the event
distributions and maximum likelihood sequence (Supplementary ma-
terial: Section 1A–B) for 100 bootstrap samples of the data. The pos-
itional variance diagrams for the cross validation results show the
proportion of bootstrap samples in which event i appears at position
k of the maximum likelihood sequence.
Patient staging
Once the characteristic sequence S has been determined using the
EBM, the simplest way to assign a stage for a particular subject,
which we adopt here, is to find the stage which is assigned the highest
probability by the model, i.e. the stage,
argmaxkP Xjj S, k
  ¼ argmaxkPðkÞYk
i¼1
PðxijjEiÞ
YI
i¼kþ1
Pðxijj:EiÞ, ð2Þ
that maximizes the probability of the data given the maximum like-
lihood event sequence. As before, we make no a priori assumptions
about model stage by assuming the prior, PðkÞ, is uniform. The stage
ranges from 0 to I (the number of events). Thus the idealized model
for stage k is that all events up to and including k have occurred and
the events after k have not occurred. However, the assignment of
stage k to a particular patient does not mean they fit the model
exactly; it is simply the stage most compatible with their
measurements.
Longitudinal validation
To assess the consistency of patient staging measures longitudinally
(Fig. 3) we evaluated each patient’s stage at all follow-up time
points that met our inclusion criteria: subjects had to have measure-
ments for all biomarkers, including an MRI scan 12 months later to
calculate the boundary shift integral over a consistent time frame.
There were two follow-up time points that met these criteria: 12
months (Fig. 3A) and 24 months (Fig. 3B). We compared
each subject’s EBM stage at follow-up with their baseline EBM
stage, which was re-evaluated using the reprocessed CSF measures
so as to ensure that the CSF was processed consistently for all time
points.
Prediction of conversion
Patient staging derived from the EBM can be used to predict conver-
sion from mild cognitive impairment to Alzheimer’s disease or cogni-
tively normal to mild cognitive impairment (Table 2) by categorizing
subjects according to their EBM stage at baseline. We performed a
binary classification of mild cognitive impairment subjects into those
who have a stable diagnosis of mild cognitive impairment (MCI-stable)
and those who convert to Alzheimer’s disease (MCI-converters), and
cognitively normal subjects into those who have a stable diagnosis of
cognitively normal (CN-stable) and those who convert to mild cogni-
tive impairment (CN-converters), by thresholding on patient EBM
stage. Stable subjects were defined as those with a mild cognitive
impairment or cognitively normal diagnosis who remained with the
same diagnosis at the end of a 12-, 24-, 36-, 48- or 60-month
follow-up period. Converters were defined as those with a mild cog-
nitive impairment or cognitively normal diagnosis who were diagnosed
with Alzheimer’s disease or mild cognitive impairment, respectively, at
the end of a 12-, 24-, 36-, 48- or 60-month follow-up period. We
used the EBM stage that maximizes balanced accuracy to classify sub-
jects. Balanced accuracy is the average of the sensitivity and specificity,
which is similar to accuracy but does not depend on disease preva-
lence. To test the effect of increasing EBM stage on the probability of
conversion from mild cognitive impairment to Alzheimer’s disease and
cognitively normal to mild cognitive impairment (Table 3 and Fig. 4),
we used Cox proportional hazards models where the event was con-
version to Alzheimer’s disease or mild cognitive impairment, respect-
ively and the input variables were patient EBM stage and demographic
factors: age, sex, education and APOE4 carrier status (presence of an
APOE4 allele). Time to event data for subjects who did not convert
was considered censored at their last available diagnosis. Statistical
significance was set at P5 0.05.
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Figure 1 Positional variance diagrams showing the distribution of event sequences in population subgroups. (A–D) Positional variance
diagrams of the uncertainty in the maximum likelihood event ordering estimated by taking MCMC (Markov chain Monte Carlo) samples
using the EBM. (E–H) Positional variance diagrams from cross-validation of the maximum likelihood event sequence by bootstrap
resampling of the data. These diagrams overestimate the uncertainty, giving a more conservative picture than the left hand column. Each
entry in the positional variance diagram represents the proportion of MCMC samples, in A–D, or bootstrap samples, in E–H, in which
events appear at a particular position in the sequence (x-axis). This proportion ranges from 0 in white to 1 in black. The y-axis orders
2568 | Brain 2014: 137; 2564–2577 A. L. Young et al.
(continued)
 at U
CL Library Services on Septem
ber 25, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Staging using cross-sectional data alone
To demonstrate the EBM’s ability to stage patients using purely cross-
sectional measures we repeated the patient staging by fitting the
EBM for a subset of 12 events (Supplementary Tables 1–3 and
Supplementary Figs 1–4), excluding atrophy rates. The inclusion cri-
teria were the same as used previously except follow-up MRI scans at
12 months were not required. As before, patient staging results were
evaluated for the whole population using the maximum likelihood
event sequence determined over all subjects, but with atrophy rates
removed (Supplementary Fig. 1A).
Results
Subjects
Study subject demographics are summarized in Table 1. Of the
285 subjects that met our inclusion criteria, 189 were amyloid + ,
139 were APOE + , and 123 were amyloid + APOE + .
Event sequences
Figure 1A–D shows positional variance diagrams for each popula-
tion subgroup. Each positional variance diagram shows the max-
imum likelihood event sequence and its uncertainty. Figure 1E–H
shows positional variance diagrams obtained from cross-validation
of the maximum likelihood ordering.
The event sequences in all four populations (Fig. 1A–D) showed
broad agreement with hypothetical models such as Jack et al.
(2010): CSF biomarkers were shown to be early events, followed
by atrophy rates, then cognitive test scores and hippocampal and
entorhinal volume, and finally other regional brain volumes. Cross-
validation (Fig. 1E–H) confirmed high confidence in the ordering
of these sets of events: for all populations, the ordering strongly
placed CSF and atrophy rates before cognitive test scores and
hippocampal and entorhinal volume, and the remaining regional
volume changes last.
Whole population
The maximum likelihood ordering for the whole population
(Fig. 1A) showed some departures from current thinking in neur-
ology (Jack et al., 2010), although the uncertainty was high
(Fig. 1E). First, CSF total tau occurred prior to phosphorylated
tau. It might be expected that phosphorylated tau is an earlier
marker of Alzheimer’s disease than total tau (Jack et al., 2013a),
being a more specific measure of the build-up of neurofibrillary
tangles than total tau (Blennow and Hampel, 2003), which meas-
ures associated neuronal damage. Second, both total tau and
phosphorylated tau occurred before amyloid-b1–42, whereas amyl-
oid plaque deposition is widely considered to be the initiating
Figure 1 Continued
events by the maximum likelihood sequence. Where rows have a single black block on the diagonal, such as the top five events in
the diagram for the whole population, the ordering is strong and permutations of those events are unlikely. Grey blocks, such as the
Mini-Mental State Examination (MMSE) score, entorhinal volume and hippocampal volume in the whole population, show that permuting
the order of the events has little effect on the likelihood so their ordering is weak. Ab+ = amyloid + ; Abeta = amyloid-b;
P-tau = phosphorylated tau; T-tau = total tau; RAVLT = Rey Auditory Verbal Learning Test.
Table 1 Baseline demographics for the whole population and population subgroups
Demographics Cognitively normal Mild cognitive impairment Alzheimer’s disease
All subjects n 92 129 64
Sex M/F 48/44 (52%) 82/47 (64%) 34/30 (53%)
Age (years, mean  SD) 75  5 73  7 75  8
Education (years, mean  SD) 15.6  2.9 15.9  3 15  3
APOE + / 22/70 (24%) 72/57 (56%) 45/19 (70%)
Amyloid + n 34 96 59
Sex M/F 19/15 (56%) 58/38 (60%) 31/28 (53%)
Age (years, mean  SD) 76  5 73  7 74  8
Education (years, mean  SD) 15.8  3.3 15.7  3.1 15  3.1
APOE + / 15/19 (44%) 63/33 (66%) 45/14 (76%)
APOE + n 22 72 45
Sex M/F 15/7 (68%) 39/33 (54%) 25/20 (56%)
Age (years, mean  SD) 75  6 73  6 75  7
Education (years, mean  SD) 15.6  3.4 15.8  2.9 14.6  3
APOE + / 22/0 (100%) 72/0 (100%) 45/0 (100%)
Amyloid+ APOE+ n 15 63 45
Sex M/F 10/5 (67%) 35/28 (56%) 25/20 (56%)
Age (years, mean  SD) 77  6 73  6 75  7
Education (years, mean  SD) 15.5  3.8 15.8  2.9 14.6  3
APOE + / 15/0 (100%) 63/0 (100%) 45/0 (100%)
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event in Alzheimer’s disease (Hardy and Selkoe, 2002). Third,
brain atrophy rate came before hippocampal atrophy rate, which
is at odds with the findings of MRI regional atrophy rate studies
(e.g. Scahill et al., 2002).
Amyloid + and APOE + subjects
The amyloid + , APOE + and amyloid + APOE + groups (Fig. 1B–D)
showed a distinct ordering of the CSF biomarkers: amyloid-b1–42,
phosphorylated tau, total tau, which replicated the ordering
described by hypothetical models (Jack et al., 2010, 2013a).
Cross-validation (Fig. 1F–H) of the event sequence in these
groups showed a much greater confidence in the ordering of
CSF biomarkers compared to the whole population (Fig. 1E),
which is more heterogeneous. In the amyloid + group (Fig. 1B),
brain atrophy rate was ordered before hippocampal atrophy rate,
but the ordering was weaker than the whole population. In the
APOE + and amyloid + APOE + groups (Fig. 1C–D) hippocampal
atrophy rate clearly occurred before brain atrophy rate.
Patient staging
Cross-sectional distribution of stages
Figure 2 shows the distribution of patient stages for the whole
population. All patient staging results were evaluated for the
whole population using the maximum likelihood event sequence
determined over all subjects (Fig. 1A). The distributions of EBM
stages for cognitively normal and Alzheimer’s disease subjects
were strongly separated and thresholds at middle stages classify
cognitively normal versus Alzheimer’s disease with accuracy
499%. The majority of cognitively normal subjects had no bio-
marker abnormalities, and were assigned stage 0, or abnormalities
only in CSF, and were assigned stages 1–3. A small number of
cognitively normal subjects also showed rates of atrophy events,
and were assigned stages 4–6. Most subjects with Alzheimer’s
disease had abnormal CSF, atrophy rate, cognitive symptoms
and low hippocampal and entorhinal volume, and were assigned
later stages. The majority of subjects with Alzheimer’s disease
were assigned the final stage in the progression, showing that
the model configuration that fits their data best is where all of
the events have occurred. The distribution of mild cognitive im-
pairment stages overlapped with the distribution of stages for cog-
nitively normal and Alzheimer’s disease subjects, but with a
greater concentration of subjects around the middle stages, sug-
gesting that these subjects show CSF abnormalities, abnormal
rates of atrophy, and some cognitive symptoms. To explore the
extent to which choice of cognitive test affects the staging (and
event sequence) output, we assessed the effect of adding in an
additional memory test, the Logical Memory II subscale (delayed
paragraph recall) from the Wechsler Memory Scale-Revised.
Results (not shown) confirm that using this additional cognitive
test score provides a similar distribution of patient EBM stages,
with logical memory occurring immediately before the Rey
Auditory Verbal Learning Test in the event sequence.
Longitudinal consistency
Figure 3 compares each subject’s EBM stage at baseline with their
EBM stage at 12- and 24-month follow-ups. Patient staging
showed good longitudinal consistency, with the EBM stage of
each subject generally increasing or remaining stable at each
follow-up (most points are within or above the grey shaded
area, which represents the uncertainty estimated by the EBM, as
shown in Fig. 1A). The small number of individuals whose EBM
stage decreased longitudinally (below the diagonal) by more than
the uncertainty estimated by the EBM (shaded in grey) were all
subjects who improved from an abnormal to a normal score on
one or more of the three cognitive tests (Mini-Mental State
Examination, Rey Auditory Verbal Learning Test, and ADAS-
Cog) and/or two atrophy rates (brain atrophy rate and hippocam-
pal atrophy rate) with the exception of one subject (circled in
green) whose CSF amyloid-b1–42 levels increased from a clearly
abnormal level of 139 pg/ml at baseline to a more borderline
level of 207 pg/ml at the 12-month follow-up.
Prediction of clinical outcomes
Table 2 shows the balanced accuracy, sensitivity, specificity, area
under the receiver operating characteristic (ROC) curve, and max-
imum accuracy threshold EBM stage for classification of MCI-
stable versus MCI-converters over different follow-up durations.
The balanced accuracy and area under the ROC curve of the
classification were comparable to state-of-the-art classification
techniques (Young et al., 2013). As the duration of the follow-
up increased, the maximum balanced accuracy threshold
decreased, i.e. later EBM stages were better at predicting faster
conversion times. These optimal stage thresholds suggest that ab-
normal CSF measures, atrophy rate, cognitive test scores and hip-
pocampal and entorhinal volume provide the best prediction of
conversion in 42 years, whereas just abnormal CSF, atrophy
rate and ADAS-Cog and Rey Auditory Verbal Learning Test
scores is the combination that best predicts conversion over a
period of 3 to 5 years.
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Figure 2 Proportion of patients in each diagnostic category at
each EBM stage. Proportion of cognitively normal in light blue,
mild cognitive impairment in black, and Alzheimer’s disease in
orange. Each EBM stage on the x-axis corresponds to the oc-
currence of a new biomarker transition event. Stage 0 corres-
ponds to no events having occurred and stage 14 is when all
events have occurred. Events are ordered by the maximum
likelihood event sequence for the whole population as shown in
Fig. 1A.
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The same statistics are shown in Table 2 for classification of CN-
stable versus CN-converters. Again the threshold EBM stage
decreased for increasing follow-up durations, with abnormal CSF
total tau, phosphorylated tau and amyloid-b1–42 levels best pre-
dicting conversion from cognitively normal to mild cognitive im-
pairment over a period of 44 years, but just abnormal CSF total
tau and phosphorylated tau best predicting conversion over 5
years.
Table 3 shows the hazard ratio and statistical significance of
each variable in the Cox proportional hazards models. Increasing
EBM stage was a significant hazard for conversion from both mild
cognitive impairment to Alzheimer’s disease and cognitively
normal to mild cognitive impairment. Figure 4 shows the esti-
mated probability of remaining cognitively normal or mild cogni-
tive impairment depending on baseline EBM stage.
Staging using cross-sectional data alone
We repeated all analyses for purely cross-sectional measures, i.e.
excluding rates of atrophy, to demonstrate the clinical application
of our staging system, where patients need to be staged at one
point in time. Supplementary Table 1 gives demographic
A B
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Baseline EBM stage
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
12
-m
on
th
fo
llo
w
-u
p
EB
M
st
ag
e
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Baseline EBM stage
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
24
-m
on
th
fo
llo
w
-u
p
EB
M
st
ag
e
Figure 3 Longitudinal consistency of patient staging in the whole population over a (A) 12-month and (B) 24-month follow-up period.
The size of the dot plotted at each point corresponds to the number of subjects with that particular baseline and follow-up EBM stage. The
largest dot, at (0,0) represents 19 subjects in A and seven subjects in B, and the smallest dots represent one subject. The grey shaded area
visualizes the uncertainty in the sequence estimated by the EBM (as shown in Fig. 1A). Subjects whose EBM stage is longitudinally
consistent are on or above the line y ¼ x and/or within the grey shaded area. Subjects whose CSF levels (CSF amyloid-b1–42 and/or
phosphorylated tau and/or total tau) change from an abnormal to a normal level at follow-up are circled in green.
Table 2 Classification results for discriminating MCI-stable versus MCI-converters and CN-stable versus CN-converters
using patient stage at baseline
Balanced
accuracy (%)
Sensitivity (%) Specificity (%) AUC Threshold
stage
n-c/n-s
MCI-converters versus MCI-stable
12 months 67 60 73 0.69 12 30/96
24 months 68 57 80 0.71 12 53/64
36 months 77 86 69 0.78 7 65/48
48 months 78 83 72 0.76 7 70/18
60 months 76 84 69 0.77 7 73/16
CN-converters versus CN-stable
12 months 84 100 68 0.76 3 2/90
24 months 66 67 66 0.62 3 6/83
36 months 68 63 73 0.62 3 8/73
48 months 66 58 74 0.65 3 12/49
60 months 76 75 76 0.75 2 16/38
Threshold stage is the maximum balanced accuracy EBM stage for separating stable subjects from converters. Subjects with a baseline EBM stage less than this threshold are
classified as stable and subjects with a baseline EBM stage greater than or equal to this threshold are classified as converters.
AUC = area under receiver operating characteristic curve; n-c = number of converters, n-s = number of stable subjects.
A data-driven model of sporadic AD Brain 2014: 137; 2564–2577 | 2571
 at U
CL Library Services on Septem
ber 25, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
information for the 325 subjects that met our inclusion criteria, of
which 216 were amyloid + , 159 were APOE + , and 141 were
amyloid + APOE + .
Removing atrophy rates had little effect on biomarker
ordering (Supplementary Fig. 1) or the cross-sectional distribution
(Supplementary Fig. 2) and longitudinal consistency
(Supplementary Fig. 3) of staging. Again, individuals whose EBM
stage decreased longitudinally (below the diagonal) by more than
the uncertainty estimated by the EBM (shaded in grey) improved
from a clearly abnormal to a more normal score on one or more of
the three cognitive tests (Mini-Mental State Examination, Rey
Auditory Verbal Learning Test, and ADAS-Cog) with the exception
of two subjects (circled in green) whose CSF levels (CSF amyloid-
b1–42 and/or phosphorylated tau and/or total tau) changed from
an abnormal to a more normal level at follow-up.
The balanced accuracy for predicting conversion (Supplementary
Table 2) was slightly reduced when the atrophy rates were
removed but was still high, giving a maximum balanced accuracy
of 71% (77% with atrophy rates) for conversion from mild cog-
nitive impairment to Alzheimer’s disease over 3 years, and 70%
(76% with atrophy rates) for conversion from cognitively normal
to mild cognitive impairment over 5 years. On average over all
follow-up durations, the balanced accuracy decreased by 2.6% for
predicting conversion from mild cognitive impairment to
Alzheimer’s disease, and increased by 4% for predicting conver-
sion from cognitively normal to mild cognitive impairment. Again,
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Figure 4 Estimated probability of remaining (A) mild cognitive impairment or (B) cognitively normal for different baseline EBM stages,
obtained by fitting Cox proportional hazards models. These estimated probabilities are shown for the average population demographics
(74.1 years of age, 15.6 years of education, APOE , male sex). Stages are grouped so that normal (blue) = stage 0, CSF (green) = stages
1–3, atrophy (orange) = stages 4–5, cognition (cyan) = stages 6–10, which includes hippocampal and entorhinal volume as well as
cognitive test scores, volume (magenta) = stages 11–14. See Supplementary Fig. 5 for an extended version of this figure, which includes a
table of the number of subjects at risk at each follow-up time point. MCI = mild cognitive impairment; CN = cognitively normal.
Table 3 Hazard ratios with 95% confidence intervals (CI) for conversion from mild cognitive impairment to Alzheimer’s
disease, and cognitively normal to mild cognitive impairment, obtained by fitting uncorrected and corrected Cox propor-
tional hazards models
Hazard ratio (CI) P-value Corrected hazard
ratio (CI)
Corrected P-value
MCI to Alzheimer’s disease progression
EBM stage 1.15 (1.09–1.21) 1.58  107* 1.15 (1.09–1.21) 2.06  107*
Age 0.99 (0.96–1.03) 0.68 0.99 (0.96–1.02) 0.49
Education 0.98 (0.91–1.05) 0.55 0.98 (0.90–1.05) 0.51
APOE4 carrier 1.55 (0.97–2.48) 0.065 1.19 (0.73–1.94) 0.49
Male 0.77 (0.49–1.23) 0.28 0.85 (0.50–1.45) 0.55
Cognitively normal to MCI progression
EBM stage 1.34 (1.07–1.69) 0.012* 1.31 (1.02–1.68) 0.033*
Age 0.99 (0.90–1.09) 0.84 0.98 (0.89–1.08) 0.67
Education 1.03 (0.88–1.22) 0.69 1.02 (0.86–1.20) 0.83
APOE4 carrier 3.15 (1.19–8.30) 0.021* 2.47 (0.85–7.17) 0.096
Male 1.75 (0.65–4.74) 0.27 1.45 (0.49–4.28) 0.5
*P5 0.05. MCI = mild cognitive impairment.
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increasing EBM stage was a significant hazard for conversion from
both mild cognitive impairment to Alzheimer’s disease and cogni-
tively normal to mild cognitive impairment (Supplementary Table 3
and Supplementary Fig. 4).
Discussion
We have adapted the EBM for use with multi-modal sporadic
disease data sets to determine the characteristic ordering of bio-
marker transitions and provide a staging system for disease moni-
toring. We use the EBM here to derive characteristic biomarker
orderings in Alzheimer’s disease from various subgroups of the
ADNI data set and to provide insight into the variability of the
ordering. The orderings provide detailed information on the dy-
namics of large sets of biomarkers across the full duration of
Alzheimer’s disease progression. They describe a distinct sequence
of biomarker transitions in which CSF measures are the earliest to
become abnormal, followed by atrophy rates, and finally cognitive
test scores and regional brain volumes. The recovered ordering
shows less variation in the sequence for amyloid + , APOE + or
amyloid + APOE + individuals than for the whole population,
most likely reflecting that the former are a more homogeneous
group with archetypical Alzheimer’s disease pathology. The results
of the EBM provide entirely data-driven support for hypothetical
models of Alzheimer’s disease progression, such as Aisen et al.
(2010), Frisoni et al. (2010) and Jack et al. (2010), without the
requirement for determining biomarker cut-points (Bartlett et al.,
2012).
The staging system provides a much more detailed evaluation of
patient state than clinical diagnoses. Importantly, it has clear clin-
ical relevance, providing a high accuracy classification of cogni-
tively normal versus Alzheimer’s disease subjects, predicting
conversion from mild cognitive impairment to Alzheimer’s disease
and cognitively normal to mild cognitive impairment, and being
applicable not only to short-term longitudinal data sets (allowing
atrophy measurements), but also to fully cross-sectional data sets
(one visit).
Event sequence
Ordering of cerebrospinal fluid biomarkers
The ordering of the CSF biomarkers in amyloid + and APOE +
individuals supports the ordering of CSF biomarkers predicted by
earlier hypothetical models of Alzheimer’s disease progression: CSF
amyloid-b1–42, phosphorylated tau, total tau. Because amyloid +
individuals are likely to have early Alzheimer’s disease, this group
should represent a much purer Alzheimer’s disease population
than the whole population and thus the biomarker ordering
should reflect the Alzheimer’s disease ordering more closely.
Similarly, APOE4 carriers would also be predicted to shown this
pattern, given the very strong association between APOE4 and
amyloid-b deposition (Andreasson et al., 2013).
In the broader population, however, our results suggest that
CSF total tau and phosphorylated tau may become abnormal
before amyloid-b1–42, i.e. that there are a significant proportion
of subjects who have CSF total tau and phosphorylated tau, but
not amyloid-b1–42 abnormalities, although cross-validation shows
higher uncertainty. Given the results in the APOE + and amyloid +
populations, it seems likely that these subjects reside predomin-
antly in the APOE and amyloid populations, and indeed esti-
mation of the ordering using the APOE and amyloid subject
groups alone supports this hypothesis, confirming that CSF total
tau and phosphorylated tau events appear earlier than CSF amyl-
oid-b1–42 (data not shown). As discussed recently (Jack et al.,
2013a; Jack and Holtzman, 2013b), there are several potential
explanations for this finding. First, that tau accumulation is a
common feature of aging. Braak and Del Tredici (2011) found
tau pathology to be present in healthy individuals at autopsy
from as early as 20 years of age. These findings are replicated
by the study of Kok et al. (2009), which found neurofibrillary
tangle deposition in a significant proportion of APOE individuals
between 30 and 59 years of age. Our results, which demonstrate
discrepancies between the ordering in APOE + and APOE indi-
viduals, would be entirely consistent with these findings, with the
pattern observed in the population as a whole reflecting a mixture
of two populations: one already on the path to developing
Alzheimer’s disease, the other undergoing normal aging, with
total tau and phosphorylated tau a common early feature in
both. A second alternative is that accumulation of tau pathology
may be an early feature of Alzheimer’s disease either for some or
all subjects. Early tau pathology may be more prevalent in APOE
and amyloid individuals, or alternatively, as the subjects re-
cruited for ADNI are age-matched, we might not observe early
tau pathology in the APOE + and amyloid + populations who
would be likely to develop Alzheimer’s disease at a younger
age, and thus already have abnormal amyloid levels. A third pos-
sibility is that amyloid accumulation does precede tau deposition,
but that either current CSF amyloid-b1–42 assays are less sensitive
than the CSF total tau and phosphorylated tau assays, or do not
detect the earliest (e.g. oligomeric) abnormal amyloid-b moieties.
Finally, as CSF total tau is not specific to Alzheimer’s disease and is
found in other neurodegenerative diseases, e.g. stroke, trauma
and encephalitis (Blennow et al., 2010), a further alternative is
that individuals have other, perhaps presymptomatic neurodegen-
erative diseases, such as frontotemporal dementa, or dementia
with Lewy bodies. Such individuals might be under-represented
in the APOE + and/or amyloid + groups, which are enriched for
Alzheimer’s disease, and thus more prevalent in the APOE and
amyloid groups.
Ordering of magnetic resonance imaging biomarkers
The ordering of MRI biomarkers from the EBM agrees with pre-
vious findings (Thompson et al., 2001; Scahill et al., 2002), with
atrophy rates becoming abnormal before overall volume changes,
and volume changes occurring in a distinct sequence, starting in
the hippocampus and entorhinal cortex, progressing to other tem-
poral lobe areas, the middle temporal gyrus and the fusiform
gyrus, with resulting overall brain volume loss and ventricular ex-
pansion. Results in APOE + subjects also support previous findings
(Schuff et al., 2009; Caroli and Frisoni, 2010), suggesting earlier
hippocampal and entorhinal volume loss, which occur before Mini-
Mental State Examination reduction in the APOE + population and
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after Mini-Mental State Examination in the whole population and
amyloid + population.
One perhaps surprising result of the MRI biomarker ordering is
that the increasing whole brain atrophy rate event occurs before
the hippocampal atrophy rate event both in the whole and amyl-
oid-b+ population. In common with any data-driven model of
biomarker changes, the EBM orders events based on when the
corresponding measurements become discernibly different be-
tween cases and controls. This may not reflect the order of ap-
pearance of underlying pathology as the precision of the
measurements may vary (Fonteijn et al., 2012). Thus, this result
might simply reflect the increased variability associated with meas-
urement of hippocampal over whole-brain atrophy rates
(Leung et al., 2013). Other possible factors are that the results
are influenced by subjects who have a mixture of pathologies,
where other processes occur alongside Alzheimer’s disease that
contribute to brain atrophy rate but not hippocampal atrophy
rate, such as vascular disease (Barnes et al., 2013), or other neu-
rodegenerative diseases (Whitwell et al., 2007). Alternatively,
excess whole brain atrophy may be a core feature of all patients
with Alzheimer’s disease, noting that some individuals with patho-
logically confirmed Alzheimer’s disease have relatively hippocam-
pal sparing disease (Whitwell et al., 2012).
Uncertainty in the event sequence
The uncertainty in the event sequence, as shown by the positional
variance diagrams and cross-validation results, potentially provides
useful information about the variation of biomarker ordering
across the population. However, three main factors contribute to
the uncertainty. First, natural variation: some events may occur in
different orders in different individuals. For example, for APOE +
subjects, hippocampal volume loss may occur earlier than in
APOE subjects (Schuff et al., 2009; Caroli and Frisoni, 2010);
thus in the whole population that combines both groups, uncer-
tainty is higher. Second, sampling density: when events occur in
close succession, there are likely to be fewer of the data points,
which are required to determine their ordering, that separate
them. Third, outliers: the data set may include subjects who do
not follow any typical progression pattern of Alzheimer’s disease,
e.g. subjects with other neurodegenerative diseases. Although the
model fitting procedure we use is somewhat robust to these out-
liers, they can still affect the posterior distribution on the ordering,
which manifests as uncertainty.
Using the event-based model to define cut points
A major advantage of the EBM is that the ordering of biomarkers
is not dependent on cut points. Instead, the EBM is probabilistic,
calculating the probability that each event has occurred from
models of the distributions of normal and abnormal biomarkers
learned from the data rather than assuming an event has occurred
when a certain threshold value is reached. However, for compari-
son we derived cut point values, given in Table 4, which represent
the point at which the biomarker value is equally likely to be
normal or abnormal, and should therefore be similar to existing
biomarker cut points. The resulting cut points for the CSF bio-
markers are similar to those reported by Shaw et al. (2009),
which were derived using a maximum accuracy classification of
autopsy confirmed Alzheimer’s disease versus healthy controls.
Importantly, the ordering provided by the EBM can be seen not
merely to reflect the ordering of the sensitivity or specificity of
these cut points.
Patient staging
A more directly practical output of the EBM is the data-driven
staging system it provides. Here we demonstrate, for the first
time, the use of such a patient staging measure to predict clinical
outcomes. Our staging measure strongly separates cognitively
normal and Alzheimer’s disease subjects and gives comparable re-
sults to state-of-the-art classification techniques for prediction of
conversion from mild cognitive impairment to Alzheimer’s disease
(Young et al., 2013), albeit with a larger set of biomarkers. The
major advantage of the EBM, a generative model, is that it expli-
citly provides useful information on what drives the classification,
unlike the discriminative models used in Young et al. (2013). We
used the EBM’s staging system to predict conversion from cogni-
tively normal to mild cognitive impairment, as well as mild
cognitive impairment to Alzheimer’s disease, and over different
follow-up durations. The classification results are supported by
the results of the Cox proportional hazards models, which find
EBM stage to be a significant hazard for conversion from both
mild cognitive impairment to Alzheimer’s disease and cognitively
normal to mild cognitive impairment. This suggests that the EBM,
once sufficient control/Alzheimer’s disease data are available,
might have clinical application, providing valuable prognostic
Table 4 Cut point values derived using the event
distributions estimated by the EBM
Biomarker Cut point Sensitivity
(%)
Specificity
(%)
Amyloid-b (pg/ml) 189 92 63
Phosphorylated tau
(pg/ml)
25 88 71
Total tau (pg/ml) 80 77 73
Hippocampal atrophy
(ml/year)
0.138 72 75
Brain atrophy (ml/year) 11.9 64 78
RAVLT 33 92 91
ADAS-Cog 17 97 97
MMSE 27 100 97
Hippocampus (% TIV) 0.423 81 82
Entorhinal (% TIV) 0.214 84 83
Mid temporal (% TIV) 1.19 75 78
Whole brain (% TIV) 64.6 73 66
Fusiform (% TIV) 1.05 73 73
Ventricles (% TIV) 3.04 48 85
Volume measurements (hippocampus, entorhinal, mid temporal, fusiform, whole
brain, ventricles) are summed over the left and right hemisphere and total intra-
cranial volume normalized, and are recorded as a percentage of the total intra-
cranial volume. The sensitivity is the percentage of Alzheimer’s disease subjects
with abnormal measurements, and specificity is the percentage of cognitively
normal subjects with normal measurements, when subjects are classified using
these cut points.
MMSE = Mini-Mental State Examination; RAVLT = Rey Auditory Verbal Learning
Test; TIV = total intracranial volume.
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information on an individual patient basis, and potentially for clin-
ical trial stratification.
Model assumptions
When interpreting these results, it is important to stress that the
EBM is based on strong assumptions, which are explicitly designed
to simplify reality to determine major trends in data. This section
summarizes the key assumptions made in the modelling process,
their potential influence on results, and possibilities to relax the
assumptions in future work.
Event sequence
The EBM, like other data-driven models (Jack et al., 2011; Lo
et al., 2011; Bateman et al., 2012; Buchhave et al., 2012;
Fo¨rster et al., 2012; Landau et al., 2012; Villemagne et al.,
2013), assumes that all subjects follow a single progression pat-
tern. While this may be reasonable for the amyloid + and APOE +
groups, the wider sporadic Alzheimer’s disease is likely to show
more variability in the event sequence due to the inherent disease
heterogeneity, driven perhaps by genetic, e.g. the presence or
absence of APOE4 (Schott et al., 2006), or lifestyle factors. The
single sequence the EBM identifies maximizes compatibility within
the set of subjects. It is thus important to consider not only the
most likely sequence, but also the positional variance diagram and
cross-validation output, which explicitly highlight areas of uncer-
tainty, aiding interpretation particularly where the data depart
from the assumptions, for example in heterogeneous groups.
The positional variance diagrams generated directly from the
EBM (Fig. 1A–D) underestimate the uncertainty in the event
ordering, as they do not account for uncertainty in the biomarker
distribution models. The cross-validation results (Fig. 1E–H), on the
other hand, tend to overestimate the uncertainty, because each
iteration considers only a subset of the data. In our whole-popu-
lation analysis, both mechanisms show reasonable stability of the
results, which gives some confidence to the conclusions. However,
it is important to remember that the single sequence does not
represent all subjects and the positional variance diagrams are
only a crude indicator of heterogeneity of the event sequence.
More sophisticated models that can relax the assumption of a
single event ordering, (e.g. Beckett, 1993; Huang and
Alexander, 2012), and/or provide uncertainty estimates by model-
ling the uncertainty in the biomarker distribution parameters, are
important areas for future study.
Patient staging
Although the modelling approach provides a powerful potential
means of patient staging, it is important that such staging infor-
mation is interpreted correctly. While the idealized model for, e.g.
stage 3, is that all CSF biomarkers are abnormal and all others
are normal, a patient assigned stage 3 need not fit this profile
exactly; stage 3 is simply the idealized stage most compatible
with a given individual’s biomarker measurements. This formula-
tion enables the EBM to stage subjects who do not conform to
the maximum likelihood event sequence, which is important
given the heterogeneity of sporadic Alzheimer’s disease. Despite
its idealized nature, the staging system has clear clinical
relevance, as demonstrated by the strong classification perform-
ance and Cox proportional hazards model results; those results
also add confidence to the event sequence derived from the
whole population, which underpins the staging. The probabilistic
nature of the staging system presents opportunities for refine-
ment in future work. Here we assign only the most likely
stage, but using Equation 2 we can quantify the uncertainty in
the stage assignment, which may contain useful additional diag-
nostic and prognostic information. Moreover, also using Equation
2, we can obtain an overall likelihood of conforming to the event
sequence, which should be useful for detecting misdiagnoses or
choosing the most likely diagnosis from a selection of models for
different diseases.
Further applications
The EBM offers a range of possibilities for wider application. This
work focuses on regional imaging measures, CSF and cognitive bio-
markers. Future work will determine the ordering of other
Alzheimer’s disease biomarkers and a more extensive set of regional
imaging biomarkers as in Fonteijn et al. (2012). In particular, includ-
ing FDG and amyloid PET biomarkers, which may help separate
mild cognitive impairment subtypes (Prestia et al., 2013), and in
due course tau-PET will be of considerable interest. This may also
be possible by refining the EBM to allow for missing data, which
would enable it to recover ordering from incomplete data sets; this
would also enable reliable models of the amyloid– and APOE
groups. Currently the ADNI data set is the only freely available
data set that has a sufficiently large number of subjects, and diver-
sity of biomarkers to support the EBM analysis. Repetition of these
analyses on other Alzheimer’s disease data sets will provide import-
ant validation of our results. An EBM formulation that allows for
missing data could use a range of data sets as input, and output
combined results. Work on such a formulation requires careful stat-
istical evaluation and is on-going. Application of the EBM to other
dementias, such as the various forms of (sporadic and familial)
frontotemporal dementia, vascular dementia or dementia with
Lewy bodies, will provide insight into how the underlying patho-
logical process varies across different types of dementia. It offers the
possibility to obtain staging systems for other diseases, as we show
here for Alzheimer’s disease. Moreover, the generative nature of the
EBM enables differential diagnosis, as the EBM can assign a likeli-
hood of a particular case fitting the sequence for any particular
disease. Furthermore, the technique can be applied to any sequen-
tial mechanism, and so naturally extends to model a wide variety of
other diseases or developmental processes (such as skill acquisition
or normal aging).
Conclusion
We have developed a data-driven model for determining bio-
marker ordering and staging patients. We have used the model
with the ADNI data set to support currently hypothetical models,
but further to highlight uncertainty in those orderings and vari-
ation among different subgroups. We also demonstrate that such
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a model can provide a practical and effective staging system for
patient prognosis.
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